Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06658496 · ClinicalTrials.gov registry record
PDA for Kidneys Study
A clinical trial of Congenital Heart Disease and Patent Ductus Arteriosus, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT06658496: Recruiting study of Congenital Heart Disease and Patent Ductus Arteriosus, sponsored by University of Wisconsin, Madison.
NCT06658496 is a study of Congenital Heart Disease and Patent Ductus Arteriosus that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 45 participants, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06658496, a study of Congenital Heart Disease and Patent Ductus Arteriosus, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to gather more information on kidney oxygen levels in babies with a patent ductus arteriosus (PDA), and evaluate the relationships between kidney oxygen levels, PDA status and kidney injury. Researchers will do this by looking at ultrasound images of the heart, analyzing substances in the urine, and evaluating oxygen levels in the kidneys.
Primary Outcome
Measured through continuous renal near infrared spectroscopy (NIRS) monitoring in neonates with a PDA to those without. Echos will be obtained every 48 hours during the first 7 days of age for a maximum of 3. RSO2 will be recorded until 7 days of age.
Conditions Studied
Interventions
- DEVICE Near Infrared Spectroscopy
Study Locations (1)
Wisconsin
- Meriter Hospital, Inc. - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2027-05 |
What NCT06658496 shows while recruiting
NCT06658496 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Congenital Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which Near Infrared Spectroscopy is the first listed.
NCT06658496 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06658496 about?
NCT06658496 is a clinical study titled "PDA for Kidneys Study". The goal of this observational study is to gather more information on kidney oxygen levels in babies with a patent ductus arteriosus (PDA), and evaluate the relationships between kidney oxygen levels, PDA status and kidney injury. Researchers will do this by looking at ultrasound images of the hear...
What is the current status of trial NCT06658496?
This trial is currently recruiting. The enrollment target is 45 participants. The study started on 2024-12-19. Estimated completion is 2027-05.
What conditions does trial NCT06658496 study?
This clinical trial studies the following conditions: Congenital Heart Disease, Patent Ductus Arteriosus.
What interventions are being tested in trial NCT06658496?
The interventions under investigation include: Near Infrared Spectroscopy (DEVICE).
Who is sponsoring clinical trial NCT06658496?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06658496 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06658496's enrollment target sits among peer trials
45 47th of 63 higher than 16 of 63 other Congenital Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fontan Fitness Trial
RECRUITING · NA
-
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
RECRUITING
-
A Study of Invasive Hemodynamic for MACHD Registry
RECRUITING
-
Remote Monitoring in Pregnant Women With Congenital Heart Disease Using Wrist Wearables
RECRUITING
-
Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
RECRUITING
-
Blood Conservation in Patients (3.5-12kg) Undergoing Congenital Cardiac Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI